Switching from eculizumab to ravulizumab safely preserves renal function in atypical hemolytic uremic syndrome: Study

Results: Mean age (range) at ravulizumab initiation was 41 years (19–78 years) and 59% of the patients were female. Genetic analysis was available for all patients with 72% showing a pathogenic variant. Median time (range) on eculizumab before switching was 20 months (3–120 months). No new events of TMA or worsening of renal function were reported during up to 12 months of follow-up during ravulizumab treatment. This is the largest, non-industry derived, multi-center retrospective analysis of adult patients with aHUS switching C5-inhibitor treatment from eculizumab to ravulizumab in the real-world setting. Switching to ravulizumab was safe and efficient resulting in sustained hematological stability and preservation of renal function.

Reference:

Schönfelder, K., Kühne, L., Schulte-Kemna, L. et al. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data. BMC Nephrol 25, 202 (2024). https://doi.org/10.1186/s12882-024-03638-3